Knight Therapeutics Reports Second Quarter 2025 Results

Achieved record-high quarterly revenues since inception
Increased 2025 financial guidance

MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

Read more at globenewswire.com